LIVE WEBINAR — March 25
Winning in AI Search: How to Measure Visibility, Influence AI Recommendations, and Prove Revenue Impact

Register
Intelligence
M&A Signals
M&A Signals – Deals Announced Through March 25, 2026
  • By:Christian Banach
  • onMarch 26, 2026

Five standout M&A deals lead this week’s M&A Signals, followed by a full list of recent acquisitions and mergers worth tracking across tech, health, talent, and growth markets.

Highlights

Gilead Sciences acquired Ouro Medicines — Deal value: $1.675 billion upfront, plus up to $500 million in contingent milestone payments

Gilead Sciences is a biopharmaceutical company focused on treatments across areas, including inflammation. Ouro Medicines is a biotechnology company developing T cell engager therapies for autoimmune diseases. Gilead said the deal adds OM336, a clinical-stage BCMAxCD3 T cell engager, to its inflammation portfolio. The move...

Get Unlimited NextBigWin Access

Subscribe to become a NextBigWin Pro member and get access to all our exclusive content. Turn access and intelligence into your next big client win.

Already a member? Login
Subscribe to NextBigWin Pro
Christian Banach
Christian Banach is the founder of NextBigWin and a leader in agency growth and business development, bringing over 20 years of experience. He serves on the 4A’s Expert Network and has helped holdco agencies, such as Energy BBDO, and independents win millions in new business from brands like Disney, Toyota, and Kohl’s.